253 related articles for article (PubMed ID: 30645769)
1. Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.
Florenzano P; Pan KS; Brown SM; Paul SM; Kushner H; Guthrie LC; de Castro LF; Collins MT; Boyce AM
J Bone Miner Res; 2019 Apr; 34(4):653-660. PubMed ID: 30645769
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome.
Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM
Bone; 2023 Jun; 171():116744. PubMed ID: 36958543
[TBL] [Abstract][Full Text] [Related]
3. Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.
van der Bruggen W; Vriens D; Meier ME; Smit F; Winter EM; de Geus-Oei LF; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2980-e2994. PubMed ID: 33788944
[TBL] [Abstract][Full Text] [Related]
4. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
[TBL] [Abstract][Full Text] [Related]
5. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.
Meier ME; Clerkx SN; Winter EM; Pereira AM; van de Ven AC; van de Sande MAJ; Appelman-Dijkstra NM
J Bone Miner Res; 2021 Sep; 36(9):1729-1738. PubMed ID: 34076303
[TBL] [Abstract][Full Text] [Related]
6. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
[TBL] [Abstract][Full Text] [Related]
7. Scoliosis in Fibrous Dysplasia/McCune-Albright Syndrome: Factors Associated With Curve Progression and Effects of Bisphosphonates.
Berglund JA; Tella SH; Tuthill KF; Kim L; Guthrie LC; Paul SM; Stanton R; Collins MT; Boyce AM
J Bone Miner Res; 2018 Sep; 33(9):1641-1648. PubMed ID: 29669167
[TBL] [Abstract][Full Text] [Related]
8. Lesion Expansion in Gnathic Fibrous Dysplasia: Natural History, Indicators of Progression, and Response to Bisphosphonates.
Pan KS; Taylor J; Szymczuk V; Boyce AM
J Bone Miner Res; 2023 Oct; 38(10):1465-1471. PubMed ID: 37477421
[TBL] [Abstract][Full Text] [Related]
9. Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates.
Majoor BCJ; Papapoulos SE; Dijkstra PDS; Fiocco M; Hamdy NAT; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2019 Dec; 104(12):6069-6078. PubMed ID: 31390018
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis.
Bertin H; Moussa MS; Komarova S
Rev Endocr Metab Disord; 2023 Dec; 24(6):1103-1119. PubMed ID: 37632645
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Chapurlat RD; Delmas PD; Liens D; Meunier PJ
J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates for the treatment of fibrous dysplasia of bone.
Chapurlat R; Legrand MA
Bone; 2021 Feb; 143():115784. PubMed ID: 33276154
[TBL] [Abstract][Full Text] [Related]
13. Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.
Rotman M; Hamdy NAT; Appelman-Dijkstra NM
Br J Clin Pharmacol; 2019 Jun; 85(6):1169-1179. PubMed ID: 30471134
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.
Boyce AM; Kelly MH; Brillante BA; Kushner H; Wientroub S; Riminucci M; Bianco P; Robey PG; Collins MT
J Clin Endocrinol Metab; 2014 Nov; 99(11):4133-40. PubMed ID: 25033066
[TBL] [Abstract][Full Text] [Related]
15. Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience.
Valadares LP; de Araújo Ferreira BS; da Cunha BM; Moreira LA; Batista FGA; da Fonseca Hottz C; Magalhães GGR
Arch Endocrinol Metab; 2022 Apr; 66(2):247-255. PubMed ID: 35420267
[TBL] [Abstract][Full Text] [Related]
16. Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study.
Trojani MC; Gensburger D; Bagouet F; Cortet B; Couture G; Marcelli C; Mehsen Cetre N; Breuil V; Chapurlat R
Bone; 2023 Sep; 174():116819. PubMed ID: 37301527
[TBL] [Abstract][Full Text] [Related]
17. RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human Disease.
Palmisano B; Spica E; Remoli C; Labella R; Di Filippo A; Donsante S; Bini F; Raimondo D; Marinozzi F; Boyde A; Robey P; Corsi A; Riminucci M
J Bone Miner Res; 2019 Dec; 34(12):2171-2182. PubMed ID: 31295366
[TBL] [Abstract][Full Text] [Related]
18.
Papadakis GZ; Manikis GC; Karantanas AH; Florenzano P; Bagci U; Marias K; Collins MT; Boyce AM
J Bone Miner Res; 2019 Sep; 34(9):1619-1631. PubMed ID: 31116487
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia.
Parisi MS; Oliveri B; Mautalen CA
Bone; 2003 Oct; 33(4):582-8. PubMed ID: 14555262
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: The randomized double-blind placebo-controlled TOCIDYS trial.
Chapurlat R; Gensburger D; Trolliet C; Rouanet S; Mehsen-Cetre N; Orcel P
Bone; 2022 Apr; 157():116343. PubMed ID: 35104665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
